A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

Inclusion criteria

• Signed, written Independent Ethics Committee (IEC)/Institutional Review Board (IRB)-approved informed consent
• Age greater than or equal to 18 years
• Participants consent to provide tumor tissue collected prior to study treatment, preferably from a biopsy performed after their last anticancer therapy and within 90 days of the start of study treatment. An older archival sample may be acceptable with Sponsor approval.
• Participants must have progressed following, are intolerant of, or have no available standard-of-care therapy.
• Patients with histologically or cytologically confirmed locally advanced/metastatic relapsed or refractory solid tumors as outlined below:
• Dose Escalation and Dose Expansion (Backfill) Cohorts (BHV-1530 monotherapy):
• Participants with urothelial cancer of the urinary tract: (including renal pelvis, ureters, urinary bladder, and urethra), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) of the oral cavity, hypopharynx, oropharynx, nasopharynx, larynx and sinonasal tract.
• Tumors originating from the salivary glands, or unknown primary sites are not eligible.
• Other advanced or metastatic solid tumors with a documented activating FGFR3 alteration (mutation or fusion).
• Dose Escalation and Dose Expansion (Backfill) Cohorts (BHV-1530 in combination with cemiplimab):
• Participants with urothelial cancer of the urinary tract: (including renal pelvis, ureters, urinary bladder, and urethra), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) of the oral cavity, hypopharynx, oropharynx, nasopharynx, larynx and sinonasal tract.
• Tumors originating from the salivary glands, or unknown primary sites are not eligible.
• Other advanced or metastatic solid tumors with a documented activating FGFR3 alteration (mutation or fusion). Participants must have received ≤ 2 prior lines of systemic anti-cancer therapy which may include at most one prior anti-programmed cell death protein 1 (PD-1) (programmed death-ligand 1 \[PD-L1\]) therapy for advanced/metastatic disease. Dose Optimization Cohorts (BHV-1530 monotherapy): oParticipants with urothelial cancer of the urinary tract: (including renal pelvis, ureters, urinary bladder, and urethra)..
• Measurable advanced or metastatic tumors per RECIST 1.1 criteria
• Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Acceptable liver function:
• Bilirubin ≤ 1.5 × upper limit of normal (ULN). Participants with known Gilbert's syndrome who have total bilirubin level ≤3×ULN may be enrolled.
• AST, ALT, and alkaline phosphatase ≤ 2.5 × ULN (if liver metastases are present, then ≤ 5 × ULN is allowed)
• Acceptable renal function: • Serum creatinine ≤1.5 × ULN, or creatinine clearance ≥50 mL/min as calculated using the modified Cockcroft-Gault equation; confirmation of creatinine clearance is only required when creatinine is \>1.5 × ULN; 24-hour urine collection is allowed, but not required
• Acceptable hematologic status:
• Blood transfusion or growth factor support is not allowed within 7 days prior to blood samples that will be used to establish eligibility
• Absolute neutrophil count greater than or equal to 1500/mm3. Participants with known Duffy null phenotype who have absolute neutrophil count ≥ 1,200/mm3 may be enrolled
• Platelet count greater than or equal to 100,000 mm3
• Hemoglobin greater than or equal to 9 g/dL
• Activated partial thromboplastin time (aPTT) ≤1.5×ULN. Study participants on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for intended use
• A negative urine or serum pregnancy test (if a woman of childbearing potential);
• Women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation and for 7 months (for women) or 4 months (for men) after the last dose of study drug. General

Exclusion criteria

• Prior treatment with antibody drug conjugate (ADC) with a topoisomerase-I inhibitor payload. Prior direct treatment with topoisomerase inhibitor (e.g., irinotecan, topotecan, belotecan, nano-liposomal irinotecan) are not exclusionary.
• Participant has clinically significant intercurrent disease including, but not limited to:
• New York Heart Association Class III or IV heart failure
• Myocardial infarction, unstable angina, or stroke ≤ 6 months prior to C1D1
• Newly diagnosed thromboembolic events that require therapeutic intervention over the last 4 months prior to C1D1 (participants with stable control of lower limb deep venous thrombosis over at least 1 months are allowed, and participants with incidental, asymptomatic pulmonary embolism and clinically stable for at least 1 month prior to C1D1 are allowed)
• Severe aortic stenosis
• Uncontrolled arrhythmia
• Symptomatic pericardial effusion
• Congenital long QT syndrome
• A mean of Fredericia's formula-QT corrected interval (QTcF) prolongation to \>470 msec based on a triplicate 12-lead ECG
• Uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg) or diabetes (hemoglobin A1C ≥9.0%)
• Left ventricular ejection fraction (LVEF) \<45% determined by echocardiogram or multiple gated acquisition scan (MUGA)
• Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
• Primary central nervous system (CNS) tumors, current or previously treated leptomeningeal disease or known active brain metastases. NOTE: Participants with previously treated, clinically stable, radiologically stable brain metastases maybe eligible
• Pregnant or nursing women
• Any standard cancer therapy (e.g., chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment) or experimental therapy within 4 weeks or 5 half-lives, whichever is shorter, prior to C1D1. The interval may be reduced to 2 weeks for bone-only radiation therapy. Any major surgical procedure within 6 weeks prior to C1D1
• Participants have not recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo. If the participant has an ongoing, stable, chronic Grade 2 toxicity they may be eligible after discussion with Sponsor on a case-by-case basis
• Any clinically significant corneal or retinal abnormality that may increase the risk of eye toxicity
• Known active infection with human immunodeficiency virus (HIV), human T-cell leukemia virus, type 1 (HTLV-1), hepatitis B virus (HBV), or hepatitis C virus (HCV), if allowed by local regulations:
• Participants with hepatitis B (hepatitis B virus surface antigen \[HbsAg\] positive), or hepatitis C (hepatitis C virus \[HCV\] antibody positive, confirmed by HCV ribonucleic acid). Participants with HCV with undetectable virus after treatment are eligible. Participants with a prior history of hepatitis B virus are eligible if quantitative polymerase change reaction for hepatitis B virus DNA is negative
• Participants with human immunodeficiency virus (HIV) infection with acquired immune deficiency syndrome (AIDS) defining illness are not eligible for enrollment; however, participants who have had HIV infection and who have a cluster of differentiation 4 (CD4) + T cell count \>350 cells/μL and no history of an AIDS-defining illness are eligible for entry
• Has an active second malignancy. Note: participants with a history of malignancy that have been completely treated, with no evidence of active cancer for 3 years prior to enrollment, or participants with tumors cured with radiotherapy or surgery with low risk of recurrence (e.g., non melanoma skin cancer, histologically confirmed complete excision of carcinoma in situ) are allowed
• Participants who in the opinion of the Investigator will not be able to adhere to the schedule of assessments and/or may have difficulties complying with the treatment regimen or are unwilling or unable to comply with procedures required in this protocol
• Known sensitivity to BHV-1530 or any of the excipients in BHV-1530;
• History of (noninfectious) clinically significant interstitial lung disease (ILD)/pneumonitis that required steroids, active clinically significant ILD/pneumonitis, or suspected clinically significant ILD/pneumonitis that cannot be ruled out by imaging at screening.
• Requires supplemental oxygen for daily activities
• Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment
• Combination Specific Exclusion Criteria: To be eligible to participate in the combination arms of the study, participants must not meet the combination specific exclusion criteria in addition to the general exclusion criteria. Hypersensitivity to cemiplimab or any of its excipients or contraindicated to cemiplimab per approved local labeling. Experienced Grade 3 or higher immune-related AEs with prior treatment of anti-PD-1, anti PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137). Prior allogeneic stem cell or solid organ transplantation. Patients with history of myocarditis. Presence of cardiovascular disease, as defined by: New York Heart Association heart failure classifications of Class II, III, or IV; or myocardial infarction, or acute coronary syndrome within 12 months of first dose of study medication; or Transient ischemic attack or stroke within 1 year.